Disease-modifying genes and monogenic disorders: Experience in cystic fibrosis

Application of Clinical Genetics

Volumn 7, Issue , 2014, Pages 133-146

  Gallati, Sabina ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Candidate gene approach; Cystic fibrosis; Genome wide association studies; Genotype; Modifier genes; Phenotype

Indexed keywords

ANTIBIOTIC AGENT; BRONCHODILATING AGENT; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; PANCREAS ENZYME; STEROID; VITAMIN;

AEROBIC EXERCISE; AUTOSOMAL RECESSIVE DISORDER; CAUCASIAN; CFTR GENE; CYSTIC FIBROSIS; DIABETES MELLITUS; DISEASE SEVERITY; GENE EXPRESSION; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENOTYPE ENVIRONMENT INTERACTION; GENOTYPE PHENOTYPE CORRELATION; HUMAN; INTESTINE CELL; LIFE EXPECTANCY; LIVER DISEASE; MODIFIER GENE; MOLECULAR DIAGNOSIS; MONOGENIC DISORDER; PHENOTYPIC VARIATION; PROGNOSIS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84904318867     PISSN: None     EISSN: 1178704X     Source Type: Journal    
DOI: 10.2147/TACG.S18675     Document Type: Review

References (101)

1. Cordell HJ. Epistasis: what it means, what it doesn't mean, and statistical methods to detect it in humans. Hum Mol Genet. 2002;11(20): 2463-2468.
2. Nagel RL. Epistasis and the genetics of human diseases. C R Biol. 2005;328(7):606-615.
3. Gropman AL, Adams DR. Atypical patterns of inheritance. Semin Pediatr Neurol. 2007;14(1):34-45.
4. Slavotinek A, Biesecker LG. Genetic modifiers in human development and malformation syndromes, including chaperone proteins. Hum Mol Genet. 2003;12 Spec No 1:R45-R50.
5. Genin E, Feingold J, Clerget-Darpoux F. Identifying modifier genes of monogenic disease: strategies and difficulties. Hum Genet. 2008;124(4):357-368.
6. Rosenstein BJ, Zeitlin PL. Cystic fibrosis. Lancet. 1998;351(9098): 277-282.
7. Knowles MR, Durie PR. What is cystic fibrosis? N Engl J Med. 2002;347(6):439-442.
8. Davis PB. Cystic fibrosis since 1938. Am J Respir Crit Care Med. 2006;173(5):475-482.
9. Kerem E, Corey M, Kerem B, Durie P, Tsui LC, Levison H. Clinical and genetic comparisons of patients with cystic fibrosis, with or without meconium ileus. J Pediatr. 1989;114(5):767-773.
10. Cutting GR. Modifier genes in Mendelian disorders: the example of cystic fibrosis. Ann N Y Acad Sci. 2010;1214:57-69.
11. Ooi CY, Dorfman R, Cipolli M, et al. Type of CFTR mutation determines risk of pancreatitis in patients with cystic fibrosis. Gastroenterology. 2011;140(1):153-161.
12. Watelet JB, Van Cauwenberge P, Bachert C. Rhinological aspects of cystic fibrosis. Monaldi Arch Chest Dis. 2000;55(6):475-477.
13. Bombieri C, Claustres M, De Boeck K, et al. Recommendations for the classification of diseases as CFTR-related disorders. J Cyst Fibros. 2011;10 Suppl 2:S86-S102.
14. Riordan JR, Rommens JM, Kerem B, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science. 1989;245(4922):1066-1073.
15. Rommens JM, Iannuzzi MC, Kerem B, et al. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science. 1989;245(4922):1059-1065.
16. Tsui LC, Dorfman R. The cystic fibrosis gene: a molecular genetic perspective. Cold Spring Harb Perspect Med. 2013;3(2):a009472
17. Bradbury NA. Intracellular CFTR: localization and function. Physiol Rev. 1999;79(Suppl 1):S175-S191.
18. Bertrand CA, Frizzell RA. The role of regulated CFTR trafficking in epithelial secretion. Am J Physiol Cell Physiol. 2003;285(1):C1-C18.
19. Kim D, Steward MC. The role of CFTR in bicarbonate secretion by pancreatic duct and airway epithelia. J Med Invest. 2009; 56 Suppl:336-342.
20. Quinton PM. Role of epithelial HCO3(-) transport in mucin secretion: lessons from cystic fibrosis. Am J Physiol Cell Physiol. 2010;299(6):C1222-C1233.
21. Pezzulo AA, Tang XX, Hoegger MJ, et al. Reduced airway surface pH impairs bacterial killing in the porcine cystic fibrosis lung. Nature. 2012;487(7405):109-113.
22. Riordan JR. CFTR function and prospects for therapy. Annu Rev Biochem. 2008;77:701-726.
23. Kerem B, Rommens JM, Buchanan JA, et al. Identification of the cystic fibrosis gene: genetic analysis. Science. 1989;245(4922):1073-1080.
24. Bobadilla JL, Macek M Jr, Fine JP, Farrell PM. Cystic fibrosis: a worldwide analysis of CFTR mutations - correlation with incidence data and application to screening. Hum Mutat. 2002;19(6):575-606.
25. Welsh MJ, Smith AE. Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell. 1993;73(7):1251-1254.
26. MacDonald KD, McKenzie KR, Zeitlin PL. Cystic f ibrosis t{stroke}ransmembrane regulator protein mutations: 'class' opportunity for novel drug innovation. Paediatr Drugs. 2007;9(1):1-10.
27. Haardt M, Benharouga M, Lechardeur D, Kartner N, Lukacs GL. C-terminal truncations destabilize the cystic fibrosis transmembrane conductance regulator without impairing its biogenesis. A novel class of mutation. J Biol Chem. 1999;274(31):21873-21877.
28. Ferrari M, Cremonesi L. Genotype-phenotype correlation in cystic fibrosis patients. Ann Biol Clin (Paris). 1996;54(6):235-241.
29. Gallati S. Genetics of cystic fibrosis. Semin Respir Crit Care Med. 2003;24(6):629-638.
30. Kerem E, Corey M, Kerem BS, et al. The relation between genotype and phenotype in cystic fibrosis - analysis of the most common mutation (delta F508). N Engl J Med. 1990;323(22):1517-1522.
31. Borgo G, Gasparini P, Bonizzato A, Cabrini G, Mastella G, Pignatti PF. Cystic fibrosis: the delta F508 mutation does not lead to an exceptionally severe phenotype. A cohort study. Eur J Pediatr. 1993;152(12):1006-1011.
32. Hubert D, Bienvenu T, Desmazes-Dufeu N, et al. Genotype-phenotype relationships in a cohort of adult cystic fibrosis patients. Eur Respir J. 1996;9(11):2207-2214.
33. Salvatore F, Scudiero O, Castaldo G. Genotype-phenotype correlation in cystic fibrosis: the role of modifier genes. Am J Med Genet. 2002;111(1):88-95.
34. Kraemer R, Birrer P, Liechti-Gallati S. Genotype-phenotype association in infants with cystic fibrosis at the time of diagnosis. Pediatr Res. 1998;44(6):920-926.
35. Kraemer R, Aebi C, Casaulta Aebischer C, Gallati S. Early detection of lung disease and its association with the nutritional status, genetic background and life events in patients with cystic fibrosis. Respiration. 2000;67(5):477-490.
36. Kraemer R, Latzin P, Pramana I, Ballinari P, Gallati S, Frey U. Long-term gas exchange characteristics as markers of deterioration in patients with cystic fibrosis. Respir Res. 2009;10:106.
37. Highsmith WE, Burch LH, Zhou Z, et al. A novel mutation in the cystic fibrosis gene in patients with pulmonary disease but normal sweat chloride concentrations. N Engl J Med. 1994;331(15): 974-980.
38. Mak V, Jarvi KA, Zielenski J, Durie P, Tsui LC. Higher proportion of intact exon 9 CFTR mRNA in nasal epithelium compared with vas deferens. Hum Mol Genet. 1997;6(12):2099-2107.
39. Mekus F, Ballmann M, Bronsveld I, Bijman J, Veeze H, Tummler B. Categories of deltaF508 homozygous cystic fibrosis twin and sibling pairs with distinct phenotypic characteristics. Twin Res. 2000;3(4): 277-293.
40. Mekus F, Laabs U, Veeze H, Tummler B. Genes in the vicinity of CFTR modulate the cystic fibrosis phenotype in highly concordant or discordant F508del homozygous sib pairs. Hum Genet. 2003;112(1):1-11.
41. Vanscoy LL, Blackman SM, Collaco JM, et al. Heritability of lung disease severity in cystic fibrosis. Am J Respir Crit Care Med. 2007;175(10):1036-1043.
42. Li C, Naren AP. Macromolecular complexes of cystic f ibrosis t{stroke}ransmembrane conductance regulator and its interacting partners. Pharmacol Ther. 2005;108(2):208-223.
43. Guggino WB, Stanton BA. New insights into cystic f ibrosis: molecular switches that regulate CFTR. Nat Rev Mol Cell Biol. 2006;7(6):426-436.
44. Knowles MR, Drumm M. The influence of genetics on cystic fibrosis phenotypes. Cold Spring Harb Perspect Med. 2012;2(12):a009548.
45. Wright FA, Strug LJ, Doshi VK, et al. Genome-wide association and linkage identify modifier loci of lung disease severity in cystic fibrosis at 11p13 and 20q13.2. Nat Genet. 2011;43(6):539-546.
46. Stanke F, van Barneveld A, Hedtfeld S, Wolfl S, Becker T, Tummler B. The CF-modifying gene EHF promotes p.Phe508del-CFTR residual function by altering protein glycosylation and trafficking in epithelial cells. Eur J Hum Genet. 2014;22(5):660-666.
47. Dibbert B, Weber M, Nikolaizik WH, et al. Cytokine-mediated Bax deficiency and consequent delayed neutrophil apoptosis: a general mechanism to accumulate effector cells in inflammation. Proc Natl Acad Sci U S A. 1999;96(23):13330-13335.
48. Harris JF, Fischer MJ, Hotchkiss JR, et al. Bcl-2 sustains increased mucous and epithelial cell numbers in metaplastic airway epithelium. Am J Respir Crit Care Med. 2005;171(7):764-772.
49. Tikhmyanova N, Tulin AV, Roegiers F, Golemis EA. Dcas supports cell polarization and cell-cell adhesion complexes in development. PLoS One. 2010;5(8):e12369.
50. Pugacheva EN, Jablonski SA, Hartman TR, Henske EP, Golemis EA. HEF1-dependent Aurora A activation induces disassembly of the primary cilium. Cell. 2007;129(7):1351-1363.
51. Savastano DM, Tanofsky-Kraff M, Han JC, et al. Energy intake and energy expenditure among children with polymorphisms of the melanocortin-3 receptor. Am J Clin Nutr. 2009;90(4):912-920.
52. Getting SJ, Riffo-Vasquez Y, Pitchford S, et al. A role for MC3R in modulating lung inflammation. Pulm Pharmacol Ther. 2008;21(6):866-873.
53. Corvol H, Beucher J, Boelle PY, et al. Ancestral haplotype 8.1 and lung disease severity in European cystic fibrosis patients. J Cyst Fibros. 2012;11(1):63-67.
54. Emond MJ, Louie T, Emerson J, et al. Exome sequencing of extreme phenotypes identifies DCTN4 as a modifier of chronic Pseudomonas aeruginosa infection in cystic fibrosis. Nat Genet. 2012;44(8): 886-889.
55. Blackman SM, Deering-Brose R, McWilliams R, et al. Relative contribution of genetic and nongenetic modifiers to intestinal obstruction in cystic fibrosis. Gastroenterology. 2006;131(4):1030-1039.
56. Henderson LB, Doshi VK, Blackman SM, et al. Variation in MSRA modifies risk of neonatal intestinal obstruction in cystic fibrosis. PLoS Genet. 2012;8(3):e1002580.
57. Dorfman R, Li W, Sun L, et al. Modifier gene study of meconium ileus in cystic fibrosis: statistical considerations and gene mapping results. Hum Genet. 2009;126(6):763-778.
58. Sun L, Rommens JM, Corvol H, et al. Multiple apical plasma membrane constituents are associated with susceptibility to meconium ileus in individuals with cystic fibrosis. Nat Genet. 2012;44(5):562-569.
59. Bradley GM, Blackman SM, Watson CP, Doshi VK, Cutting GR. Genetic modifiers of nutritional status in cystic fibrosis. Am J Clin Nutr. 2012;96(6):1299-1308.
60. Patwari P, Emilsson V, Schadt EE, et al. The arrestin domain-containing 3 protein regulates body mass and energy expenditure. Cell Metab. 2011;14(5):671-683.
61. Blackman SM, Commander CW, Watson C, et al. Genetic modifiers of cystic fibrosis-related diabetes. Diabetes. 2013;62(10):3627-3635.
62. Dorfman R, Sandford A, Taylor C, et al. Complex two-gene modulation of lung disease severity in children with cystic fibrosis. J Clin Invest. 2008;118(3):1040-1049.
63. McDougal KE, Green DM, Vanscoy LL, et al. Use of a modeling framework to evaluate the effect of a modifier gene (MBL2) on variation in cystic fibrosis. Eur J Hum Genet. 2010;18(6):680-684.
64. Chalmers JD, Fleming GB, Hill AT, Kilpatrick DC. Impact of mannose-binding lectin insufficiency on the course of cystic fibrosis: a review and meta-analysis. Glycobiology. 2011;21(3):271-282.
65. Akhurst RJ. TGF beta signaling in health and disease. Nat Genet. 2004;36(8):790-792.
66. Yang YC, Zhang N, Van Crombruggen K, Hu GH, Hong SL, Bachert C. Transforming growth factor-beta1 in inflammatory airway disease: a key for understanding inflammation and remodeling. Allergy. 2012;67(10):1193-1202.
67. Silverman ES, Palmer LJ, Subramaniam V, et al. Transforming growth factor-beta1 promoter polymorphism C-509T is associated with asthma. Am J Respir Crit Care Med. 2004;169(2):214-219.
68. Chiang CH, Chuang CH, Liu SL, Shen HD. Genetic polymorphism of transforming growth factor beta1 and tumor necrosis factor alpha is associated with asthma and modulates the severity of asthma. Respir Care. 2013;58(8):1343-1350.
69. Wu L, Chau J, Young RP, et al. Transforming growth factor-beta1 genotype and susceptibility to chronic obstructive pulmonary disease. Thorax. 2004;59(2):126-129.
70. Drumm ML, Konstan MW, Schluchter MD, et al. Genetic modifiers of lung disease in cystic fibrosis. N Engl J Med. 2005;353(14):1443-1453.
71. Bremer LA, Blackman SM, Vanscoy LL, et al. Interaction between a novel TGFB1 haplotype and CFTR genotype is associated with improved lung function in cystic fibrosis. Hum Mol Genet. 2008;17(14): 2228-2237.
72. Gu Y, Harley IT, Henderson LB, et al. Identification of IFRD1 as a modifier gene for cystic fibrosis lung disease. Nature. 2009; 458(7241):1039-1042.
73. Hillian AD, Londono D, Dunn JM, et al. Modulation of cystic fibrosis lung disease by variants in interleukin-8. Genes Immun. 2008;9(6):501-508.
74. Corvol H, Boelle PY, Brouard J, et al. Genetic variations in inflammatory mediators influence lung disease progression in cystic fibrosis. Pediatr Pulmonol. 2008;43(12):1224-1232.
75. Darrah R, McKone E, O'Connor C, et al. EDNRA variants associate with smooth muscle mRNA levels, cell proliferation rates, and cystic fibrosis pulmonary disease severity. Physiol Genomics. 2010;41(1): 71-77.
76. Dorfman R, Taylor C, Lin F, et al. Modulatory effect of the SLC9A3 gene on susceptibility to infections and pulmonary function in children with cystic fibrosis. Pediatr Pulmonol. 2011;46(4):385-392.
77. Favia M, Fanelli T, Bagorda A, et al. NHE3 inhibits PKA-dependent functional expression of CFTR by NHERF2 PDZ interactions. Biochem Biophys Res Commun. 2006;347(2):452-459.
78. Stanke F, Becker T, Cuppens H, et al. The TNFalpha receptor TNFRSF1A and genes encoding the amiloride-sensitive sodium channel ENaC as modulators in cystic fibrosis. Hum Genet. 2006;119(3):331-343.
79. von Kanel T, Stanke F, Weber M, et al. Clinical and molecular characterization of the potential CF disease modifier syntaxin 1A. Eur J Hum Genet. 2013;21(12):1462-1466.
80. Gisler FM, von Kanel T, Kraemer R, Schaller A, Gallati S. Identification of SNPs in the cystic fibrosis interactome influencing pulmonary progression in cystic fibrosis. Eur J Hum Genet. 2013;21(4):397-403.
81. Viel M, Leroy C, Hubert D, Fajac I, Bienvenu T. ENaCbeta and gamma genes as modifier genes in cystic fibrosis. J Cyst Fibros. 2008;7(1):23-29.
82. Beucher J, Boelle PY, Busson PF, Muselet-Charlier C, Clement A, Corvol H. AGER -429T/C is associated with an increased lung disease severity in cystic fibrosis. PLoS One. 2012;7(7):e41913.
83. Kormann MS, Hector A, Marcos V, et al. CXCR1 and CXCR2 haplotypes synergistically modulate cystic fibrosis lung disease. Eur Respir J. 2012;39(6):1385-1390.
84. Guo X, Pace RG, Stonebraker JR, et al. Mucin variable number tandem repeat polymorphisms and severity of cystic fibrosis lung disease: significant association with MUC5AC. PLoS One. 2011;6(10): e25452.
85. Lai HC, Kosorok MR, Laxova A, Davis LA, FitzSimmon SC, Farrell PM. Nutritional status of patients with cystic fibrosis with meconium ileus: a comparison with patients without meconium ileus and diagnosed early through neonatal screening. Pediatrics. 2000; 105(1 Pt 1):53-61.
86. Blohmke CJ, Victor RE, Hirschfeld AF, et al. Innate immunity mediated by TLR5 as a novel antiinflammatory target for cystic fibrosis lung disease. J Immunol. 2008;180(11):7764-7773.
87. Blohmke CJ, Park J, Hirschfeld AF, et al. TLR5 as an antiinflammatory target and modifier gene in cystic fibrosis. J Immunol. 2010;185(12):7731-7738.
88. Ritzka M, Stanke F, Jansen S, et al. The CLCA gene locus as a modulator of the gastrointestinal basic defect in cystic fibrosis. Hum Genet. 2004;115(6):483-491.
89. Kolbe EW, Tamm S, Hedtfeld S, Becker T, Tummler B, Stanke F. CLCA4 variants determine the manifestation of the cystic fibrosis basic defect in the intestine. Eur J Hum Genet. 2013;21(6): 691-694.
90. Derbel S, Doumaguet C, Hubert D, et al. Calpain 10 and development of diabetes mellitus in cystic fibrosis. J Cyst Fibros. 2006;5(1): 47-51.
91. Blackman SM, Hsu S, Ritter SE, et al. A susceptibility gene for type 2 diabetes confers substantial risk for diabetes complicating cystic fibrosis. Diabetologia. 2009;52(9):1858-1865.
92. Frangolias DD, Ruan J, Wilcox PJ, et al. Alpha 1-antitrypsin deficiency alleles in cystic fibrosis lung disease. Am J Respir Cell Mol Biol. 2003;29(3 Pt 1):390-396.
93. Arkwright PD, Pravica V, Geraghty PJ, et al. End-organ dysfunction in cystic fibrosis: association with angiotensin I converting enzyme and cytokine gene polymorphisms. Am J Respir Crit Care Med. 2003;167(3):384-389.
94. Henrion-Caude A, Flamant C, Roussey M, et al. Liver disease in pediatric patients with cystic fibrosis is associated with glutathione S-t{stroke}ransferase P1 polymorphism. Hepatology. 2002;36(4 Pt 1): 913-917.
95. Gabolde M, Hubert D, Guilloud-Bataille M, Lenaerts C, Feingold J, Besmond C. The mannose binding lectin gene influences the severity of chronic liver disease in cystic fibrosis. J Med Genet. 2001;38(5):310-311.
96. Bartlett JR, Friedman KJ, Ling SC, et al. Genetic modifiers of liver disease in cystic fibrosis. JAMA. 2009;302(10):1076-1083.
97. Labenski H, Hedtfeld S, Becker T, Tummler B, Stanke F. Initial interrogation, confirmation and fine mapping of modifying genes: STAT3, IL1B and IFNGR1 determine cystic f ibrosis disease manifestation. Eur J Hum Genet. 2011;19(12):1281-1288.
98. Stanke F, Hedtfeld S, Becker T, Tummler B. An association study on contrasting cystic fibrosis endophenotypes recognizes KRT8 but not KRT18 as a modifier of cystic fibrosis disease severity and CFTR mediated residual chloride secretion. BMC Med Genet. 2011;12:62.
99. Li W, Soave D, Miller MR, et al. Unraveling the complex genetic model for cystic fibrosis: pleiotropic effects of modifier genes on early cystic fibrosis-related morbidities. Hum Genet. 2014;133(2):151-161.
100. Dorfman R. Modifier gene studies to identify new therapeutic targets in cystic fibrosis. Curr Pharm Des. 2012;18(5):674-682.
101. Dipple KM, McCabe ER. Modifier genes convert "simple" Mendelian disorders to complex traits. Mol Genet Metab. 2000;71(1-2): 43-50.